ADPT President and COO Julie Rubinstein Sells $291K of Stock

On October 22, 2026, Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation (ADPT), sold 11,881 shares for about $291,205. This transaction was reported in a Form 4 filing with the SEC. The sale was part of a planned trading strategy.

Following this sale, Rubinstein now owns 377,802 shares, which is a decrease of about 3.05% from her previous holdings. The shares were sold at an average price of $24.51 each, just above the closing price of $24.41 on the same day.

ADPT Adaptive Biotechnologies Corporation

$25.51 ▲ +60.34% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Other Institutional Activity in Adaptive Biotechnologies

Several other institutional investors have also been active in Adaptive Biotechnologies. Shaw D.E. & Co., Inc. increased its holdings by 2,660,252 shares, bringing its total to 4,625,859 shares valued at about $121.5 million. Meanwhile, Westfield Capital Management Co. LP reduced its stake by 1,168,845 shares, ending with 4,267,645 shares worth around $112.1 million. Viking Global Investors, L.P. maintained its position with 29,993,708 shares valued at approximately $787.9 million.

Adaptive Biotechnologies Corporation Stock Up 7.6%

The stock of Adaptive Biotechnologies closed at $24.41 on October 22, 2026, and has recently traded around $26.27, which is about 7.6% higher than the closing price. The shares are currently above their 50-day moving average of $26.14 and significantly above their 200-day average of $19.35. However, the stock is still below its 52-week high of $30.74, indicating some room for growth.

Recent Earnings

In its latest earnings report, Adaptive Biotechnologies posted a revenue of approximately $308.1 million for the trailing twelve months. The company is scheduled to report its next earnings on November 4, 2026. The revenue growth year-over-year stands at 21.5%, although the company has a negative net margin of -20.7%.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

Julie Rubinstein has been active in selling shares of Adaptive Biotechnologies. On October 16, 2026, she sold 11,881 shares at an average price of $24.24, totaling about $288,010.89. She continued with further sales on October 19, 20, and 21, with prices ranging from $24.05 to $25.41, accumulating a total of about $1.1 million from these transactions.

Analysts Set New Price Targets

Analysts have been optimistic about Adaptive Biotechnologies. On September 22, 2026, BTIG maintained a "Buy" rating with a price target of $34. On September 29, 2026, Goldman Sachs initiated coverage with a "Buy" rating and a target of $35. The consensus among analysts suggests a strong buy rating with a mean price target of $30.21.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation develops a platform for immune medicine, focusing on the diagnosis and treatment of various diseases. The company uses advanced technologies like immunosequencing to generate clinical data that helps decode the adaptive immune system. This event highlights the ongoing interest in the company's stock and its potential for growth in the healthcare sector.

Bottom Line

Investors should keep an eye on Adaptive Biotechnologies as it approaches its next earnings report on November 4, 2026. With several analysts maintaining positive ratings and price targets, the stock may attract further attention in the market.